Miami Breast Cancer Conference

For 37 years, the multidisciplinary Miami Breast Cancer Conference has met this educational need—bringing together surgical, medical, and radiation oncologists, as well as geneticists, pathologists, radiologists, and supportive care specialists—to improve the care for patients with breast cancer.
Tucatinib and neratinib show encouraging activity in patients with advanced breast cancer and central nervous system metastases. Read More ›

Alterations in CDK and PI3K pathways are frequent in breast cancer brain metastases; could targeting these genetic alterations lead to improved survival? Read More ›

New research reveals that brain metastases harbor distinct clinically actionable genetic alterations compared with primary tumors and extracranial metastases. Read More ›


DS-8201 yields exciting results in HER2-positive, TDM-1 resistant, or refractory metastatic disease, but providers should remain vigilant about the incidence of interstitial lung disease. Read More ›

With several new therapies on the horizon for HER2-positive metastatic breast cancer, tucatinib stands out for its notable activity in patients with brain metastases. Read More ›

Treatment options continue to emerge for patients with HER2-positive advanced breast cancer, with some generating more buzz than others. Read More ›

Should all patients with HER2-positive tumors between 1 cm and 2 cm receive neoadjuvant chemotherapy? Experts weigh in. Read More ›


Central nervous system objective responses were observed in patients with HER2-positive metastatic breast cancer treated with neratinib in 3 separate clinical trials. Read More ›